expect focu distributor revert back company-specif issu
macro environ notabl brand inflat stabil focu
guidanc expect come rel conserv rang
dplo expect turnaround castiarx focal point
recent comment drug distributor well survey result
recent ahead curv report publish cowen
team indic brand inflat stabil mid-singl digit rang
think focu revert back company-specif issu distributor
addit rule new york stewardship act unconstitut could provid
upsid expens associ act assum
look detail regard remedi effort pharmedium
fusion implement lash despit headwind pharma
segment expect grow see revers headwind drive
continu growth
expect focu medic segment particularli cordi management
work toward return profit growth end also look
anyth increment management busi review progress alreadi identifi
save end end
announc john hammergren retir brian tyler
appoint ceo effect april look chang strateg direct
also expect investor focu reimburs environ
franc challeng
recent concern around headwinds/tailwind ahead guidanc like keep
share range-bound report feb particularli given headwind beyond
rebat guarante see upsid potenti come aet faster
expect synergi captur expect manag guid conserv start
surpris see ep guidanc rang believ guidanc
could act clear event given attract valuat would expect share
start perform better past earn
expect focu quarter castiarx under-perform alreadi low
expect preliminari guidanc impli pbm revenu declin
y/i specif look updat regard fill posit vacat
departur mr saban mr thigpen well greater visibl sale pipelin
whether castiarx win new busi assum guidanc rang make
chang model lower pt ahead earn particularli assumpt
continu declin pbm return growth
pleas see page report import disclosur
thomson eikon cowen compani
iqvia cowen compani
million expect per share data
thomson eikon cowen compani
changedistribut oper oper bpsnanaoth oper oper bpsnanatot gross gross oper oper bpsadj pharmedium remedi expect management provid updat regard progress remedi effort memphi facil recal management note last quarter earn call commit fda restart commerci oper memphi facil get feedback fda doj civil divis result remedi effort memphi facil well effort enhanc qualiti procedur test open facil volum expect consider y/i note guidanc assum scenario pharmedium contribut downsid risk guidanc slowdown pharmedium updat lash consult busi look management commentari regard progress lash consult busi given under-perform drag segment oper profit growth guidanc headwind relat fusion implement work migrat exist custom last quarter management note made substanti progress custom migrat expect return normal level growth guidanc expect management reaffirm guidanc adj ep given one quarter fiscal year addit macro fundament brand inflat gener deflat appear track in-line management guidanc assumpt cowen estimatesconsensu estim cowen
million expect per share data
thomson eikon cowen compani
changepharmaceut oper oper bpsnanamed oper oper bpsnanatot bpsadj oper oper bpsadj busi review process look updat regard management comprehens top-down bottom-up review busi on-going process last quarter track deliv annual cost save excess end management continu look effici management expect invest save back busi drive organ growth progress cordi turnaround look detail progress management turnaround plan cordi path profit growth end particularli see execut turnaround plan key indic whether posit return growth non-recurring headwind anniversari last quarter management note made meaning progress see improv inventori management demand plan cost see potenti upsid guidanc believ could upsid management adj ep guidanc due tax recent rule new york stewardship act recal last quarter management maintain guidanc despit consider lower expect tax rate contribut decemb district judg manhattan rule new york stewardship act unconstitut would posit impact profit said note may earli remov expens associ act guidanc new york may appeal estimatesconsensu estimatesmarket performr cowen
million expect per share data
thomson eikon cowen compani
changeu pharma specialti pharma specialti oper pharma specialti oper bpsnanaeuropean pharma pharma oper pharma oper bpsnanamedical-surg oper oper bpsnanaoth oper oper bpsnanatot bpsadj oper bpsadj transit announc john hammergren retir appoint brian tyler ceo effect april look chang strateg direct transit complet particularli given recent challeng updat reimburs environ franc look updat challeng reimburs environ franc put consider pressur european pharma solut segment recal complet cost-sav program off-set impact reimburs cut includ store closur divestitur due addit cut effort fulli off-set reimburs headwind recent confer management note modestli encourag recent announc nh regard pharmaci fund pleas see role commun pharmaci nh plan detail progress upcom contract renew number notabl custom contract renew next coupl year look detail regard progress renew look increment detail regard recent announc expand distribut agreement notabl margin headwind new term contract next contract renew follow albertson va statu ipo look updat regard progress ipo management expect exit invest recal analyst day management provid timelin ipo septemb tax-fre distribut sharehold septemb howev base convers management ipo expect occur distribut sharehold like month later origin septemb time-frame cowen estimatesconsensu estim cowen
million expect per share data
thomson eikon cowen compani
changepbm oper oper bpsnanatot adjust oper oper bpsnanapharmaci bpsnanafront-end bpsnanatot bpsnananet gross gross bpsadj management provid rel conserv guidanc recent concern around headwinds/tailwind ahead guidanc like keep share range-bound report feb particularli given headwind beyond rebat guarante see upsid potenti come aet faster expect synergi captur expect management guid conserv start surpris see ep guidanc rang believ guidanc could act clear event given attract valuat would expect share start perform better past earn focu rebat guarante expect management address headwind rebat guarante due moder brand inflat investor myopic focus particular headwind base analysi expect rebat guarante oblig greater y/i headwind moder longer issu thereaft updat integr effort synergi captur look detail regard progress made far integr aet recal establish integr manag offic imo ensur smooth transit lay path synergi second full year oper ration corpor function procur formulari align medic cost reduct progress pilot program intend four pilot program launch focus chronic diseas manag readmiss prevent expect management highlight progress pilot alreadi launch well discuss potenti pilot would give investor greater insight management expect execut long-term strategi reduc medic cost cowen estimatesconsensu estim cowen
million expect per share data
thomson eikon cowen compani
changenet bpsadjust ebitda bpsadj performupd turnaround castiarx expect focu turnaround effort castiarx under-perform alreadi low expect preliminari guidanc impli y/i declin revenu due medicar part loss increment client loss revenu impact renew new busi new busi pipelin expect remaind given disappoint perform pbm segment management focus turn around pbm busi goal demonstr posit momentum ceo brian griffin directli overse castiarx current order right ship management look put place strong leadership departur mr saban mr thigpen expand sale account management team drive better client retent look detail regard management intend turn around castiarx posit growth pbm preliminari guidanc expect dplo reaffirm preliminari guidanc provid earlier month management expect total revenu specialti segment compris pbm segment compris rel adj ebitda expect flat low-singl digit net debt/ebitda also expect year-end updat estim price target rais adj ebitda estim respect conform management updat guidanc preliminari guidanc notabl updat model assum continu declin pbm return growth lower price target base revis dcf analysi impli share trade adj ebitda estim cowen estimatesconsensu estim cowen
thomson eikon cowen compani
million except per share data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per share data
cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per share data
cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per share data
cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep chang year-over-year oper incom continu continu year end june cowen
million except per share data
cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
cowen compani
asset trade receiv merchandis prepaid expens asset held sale discontinu ops- current pp goodwil total current liabil current portion long-term account accru liabil busi held sale disc ops- current long-term defer tax redeem non-controlling stockhold equiti common retain common share cumul foreign currenc non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci gain sale provis loss account charg reorg busi gain sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci gain sale asset loss debt extinguishment- gain sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal securities- proce divestitur dispos held sale assets- proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting consideration- net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- reclassfii asset held sale- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end march cowen
million except per share data
cowen compani
gross gross chang oper oper incom pre-tax pre-tax incom tax incom cont op attribut net incom attribut non-controlling net incom attribut net incom deal-rel net incom cont op includ non-recurring net incom non-recurring fulli dilut adj chang incom attribut year end march cowen
million except per share data
cowen compani
gross gross chang oper oper incom pre-tax pre-tax incom tax incom cont op attribut net incom attribut non-controlling net incom attribut net incom deal-rel net incom cont op includ non-recurring net incom non-recurring fulli dilut adj chang incom attribut cowen
million
cowen compani
cash receiv inventori prepaid expens current properti plant equip intang asset equiti method invest chang healthcare- non-current total liabil draft account short-term defer current portion long-term accru total current long-term long-term defer tax non-current redeem non-controlling stockhold equiti common addit paid-in retain accumul comprehens treasuri non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest debt ratio return invest capit averag total asset averag stockhold equiti march cowen
million
cowen compani
income/ loss flow oper activ depreci goodwil asset impair defer tax share-bas compens charg credit associ last-in-first-out inventori loss gain sale busi equiti non-cash chang oper asset liabil receiv draft account defer net cash oper acquisit busi proce sale properti acquisit capit softwar issuanc common share dividend proceeds/ repay debt effect exchang rate chang cash cash net increase/ decreas cash equival begin cash equival end summari capit owner financ non-recur fiscal year end march cowen
million
compani report cowen compani
activitiesnet adjust reconcil net cash provid oper gain healthcar technolog net asset exchang net- goodwil asset impair loss equiti method invest chang healthcare- defer share-bas compens charg credit associ last-in-first-out inventori loss gain sale busi equiti investments- non-cash chang oper asset liabil net draft account defer claim litig settlement payment- net cash provid oper invest activitiespay properti plant capit softwar acquisit net cash cash equival proce sale busi asset payment receiv healthcar technolog net asset exchang net- restrict cash acquisitions- net cash use invest financ activitiesproce short-term repay short-term proce issuanc long-term repay long-term payment debt extinguishments- common stock share repurchas includ share surrend tax dividend net cash use financ effect exchang rate chang cash cash net decreas cash cash cash equival begin cash equival end fiscal year end march cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang net work terminal- valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per share data
cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens expenses- pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu operations- net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut end decemb cowen
million except per share data
cowen compani
interseg net good interseg net cost good gross gross chang oper oper chang intang interest expens pre-tax pre-tax chang adj incom tax provis effect tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut intang loss earli extinguish debt- loss discontinu net loss non-controlling acquisition-rel financ non-recur net weight averag dilut share adj ebitda chang chang y/i net net incom attribut cowen
million
cowen compani
cash short-term account receiv defer incom current current properti equip intang asset total liabil account claim discount accru short-term debt- current portion long-term current long-term defer incom non-curr redeem non-controlling stockhold equiti common treasuri share held capit retain accumul comprehens total health sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti decemb cowen
million
cowen compani
income/ loss adjust requir reconcil net incom net cash provid oper activ depreci goodwil loss settlement defin benefit pension stock-bas defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur exclud non-recur itemsyear end decemb cowen
million
compani report cowen compani
activitiesnet adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv current account payabl claim discount accru long-term net cash provid oper invest activitiespurchas properti proce sale-lease-back proce sale properti equip acquisit net cash acquir purchas available-for-sal sale matur available-for-sal net cash use invest financ activitiesincreas decreas short-term proce issuanc long-term repay long-term purchas non-controlling interest subsidiary- payment conting consideration- dividend proce exercis stock payment tax relat net share settlement equiti repurchas common other- net cash provid use financ effect exchang rate net decreas cash cash cash equival begin cash equival end year end decemb cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per share data
cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit chang fair valu redeem common shares- termin exist stock redempt agreement- equiti loss impair non-consolid entity- restructur impair charge- non-recurring incom incom incom tax tax amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net end decemb cowen
million except per share data
cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit restructur impair charge- non-recurring incom incom incom tax tax net amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net cowen
million
cowen compani
asset account receiv defer incom prepaid expens current total current properti equip capit softwar intern use definite-liv intang asset invest non-consolid defer debt issuanc non-current total current liabil account borrow line credit- short-term debt includ current portion long-term accru expens conting compens total current long-term debt less current conting consider less current portion- defer incom non-current liabilities- mandatorili redeem common shares- total stockhold equiti common addit paid-in retain total dplo sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest debt ratio return invest capit averag total asset averag stockhold equiti cowen
million
cowen compani
flow oper activ depreci chang fair valu conting conting consider payment- net provis doubt share-bas compens defer incom tax impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang oper asset liabil account account payabl asset net cash oper acquisit expenditur capit softwar intern expenditur issuanc common purchas treasuri stock- proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end decemb cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net incom net cash use oper activ depreci asset chang fair valu conting consideration- conting consider payment- net provis doubt share-bas compens equiti loss non-consolid defer incom tax expense- impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang fair valu redeem common termin exist stock redempt agreement- certain expens paid notes- chang oper asset liabil account account payabl asset net cash use oper flow invest activ payment acquir busi net cash expenditur capit softwar intern expenditur properti capit invest loan non-consolid net cash use invest flow financ activ net payment line proce long-term debt- payment long-term proce public offer net transact costs- proce sale prefer stock net transact costs- payment made repurchas common stock- payment made repurchas stock options- proce issuanc stock upon stock option exercises- excess tax benefit relat share-bas awards- payment debt issuanc conting consider payments- sharehold net cash use provid financ net decreas increas cash equival begin period- equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
